Angiotensin Receptor Blockers for Hypertension, Heart Failure, and Chronic Kidney Disease

Introduction to ARB Selection

The American College of Cardiology recommends losartan (50-100 mg daily) or irbesartan (150-300 mg daily) for diabetic nephropathy with macroalbuminuria, based on the strongest renal outcome evidence, with losartan being the only ARB with FDA-approved indication specifically for reducing hard renal endpoints in type 2 diabetic nephropathy 1

The American Diabetes Association recommends losartan as the first-line choice for diabetic kidney disease with macroalbuminuria, based on the RENAAL trial, which demonstrated a 16% reduction in the composite endpoint of doubling serum creatinine, ESRD, or death, with 25% reduction in sustained doubling of serum creatinine and 29% reduction in ESRD 1
The National Kidney Foundation recommends irbesartan as equally effective, based on the IDNT trial, showing similar renoprotective efficacy in type 2 diabetic nephropathy with macroalbuminuria 1
The European Society of Cardiology recommends ACE inhibitors or ARBs as first-line therapy for patients with diabetes, hypertension, and albuminuria, titrated to the highest approved dose tolerated 2, 3

The American Heart Association recommends starting losartan at 50 mg daily, titrating to 100 mg daily if blood pressure goal not achieved and medication tolerated, with a dose-dependent renoprotective effect 1
The European Society of Hypertension recommends using irbesartan 150-300 mg daily based on clinical response 4

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend enhancing efficacy with thiazide or loop diuretics, as 60-90% of patients in major ARB trials used concomitant diuretics 1
The American College of Cardiology recommends never combining ARB + ACE inhibitor, as this increases adverse events without mortality benefit, demonstrated in multiple long-term studies 2, 3

The National Kidney Foundation recommends monitoring serum creatinine, potassium, and blood pressure within 2-4 weeks of initiation or dose increase, and continuing ARB therapy unless serum creatinine rises by more than 30% within 4 weeks following initiation or dose increase 3

The American College of Obstetricians and Gynecologists recommends avoiding ARB use during pregnancy, as it causes fetal toxicity, including oligohydramnios, fetal lung hypoplasia, skeletal deformations, and neonatal death when used during second and third trimesters 1
The European Society of Cardiology recommends avoiding concomitant use with aliskiren in patients with diabetes, and using ARBs with caution in patients with symptomatic hypotension, uncontrolled hyperkalemia, or bilateral renal artery stenosis 1, 2

The American Diabetes Association recommends ARBs as first-line therapy for patients with diabetes, hypertension, and albuminuria, and should be titrated to the maximum approved dose tolerated 5, 6, 7
ARBs reduce major cardiovascular events in patients with diabetes and established cardiovascular disease or multiple risk factors 5

ARBs reduce heart failure hospitalization risk, particularly when combined with beta-blockers in patients with reduced left ventricular ejection fraction 7
ACE inhibitors or ARBs reduce progression to symptomatic heart failure by 20-37% in patients with asymptomatic left ventricular dysfunction after myocardial infarction 7

For patients with diabetes and hypertension, the American Heart Association suggests that ARBs can be used as first-line therapy for renal protection 5, 6, 7
The target blood pressure for diabetic patients is <130/80 mmHg 6

Most patients require 2-3 antihypertensive agents to reach target blood pressure, and adding a thiazide or loop diuretic is a preferred combination 6
Serum creatinine, potassium, and blood pressure should be monitored within 2-4 weeks of initiation or dose change 5, 6, 7

Losartan reduces proteinuria by approximately 35 % independent of blood‑pressure lowering in patients with hypertension, chronic kidney disease, and type 2 diabetes (Level 1 evidence from the RENAAL trial) 8, 9.

Irbesartan provides renoprotective efficacy comparable to losartan in type 2 diabetic nephropathy with macroalbuminuria (Level 1 evidence from the IDNT trial) 8, 9.
Irbesartan is superior to amlodipine and placebo in slowing the decline of glomerular filtration rate in the same patient population (Level 1 evidence from the IDNT trial) 8, 9.

The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend that either an ARB or an ACE inhibitor be used for hypertensive patients with type 2 diabetes and macroalbuminuria, and state that ARBs are more effective than other antihypertensive classes in slowing progression of kidney disease characterized by macroalbuminuria (Guideline recommendation) 8, 9.